Skip to main content
Netramark Holdings Inc. logo

Netramark Holdings Inc. — Investor Relations & Filings

Ticker · AIAI ISIN · CA64119M1059 LEI · 391200VOK8WHERIX0Q06 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-05-18 Regulatory Filings
Country CA Canada
Listing CSE AIAI

About Netramark Holdings Inc.

https://www.netramark.com/

Netramark Holdings Inc. develops and deploys advanced Artificial Intelligence (AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, focusing on optimizing clinical trial design and outcomes. Its core product, NetraAI, is an AI platform powered by the proprietary Attractor AI algorithm. NetraAI analyzes complex, multimodal clinical trial datasets to uncover hidden patient correlations and causal factors, providing high clarity and explainability. The platform delivers AI-powered insights to trial sponsors, clinical research organizations, and biotechnology companies. These insights are used to inform protocol design, identify optimal patient subpopulations, determine effective dosage, enhance enrichment strategies, and improve inclusion/exclusion criteria, thereby increasing effect sizes and minimizing clinical trial risks.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CEO of NetraMark Holdings Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3018 characters), consistent with a certification letter rather than a full report.
2023-05-18 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management Discussion & Analysis For the Three and Six Months ended March 31, 2023' and contains detailed discussion of the company's business operations, liquidity, capital resources, and financial results for the interim period ending March 31, 2023. It references unaudited condensed interim consolidated financial statements prepared under IFRS and International Standard 34 for interim financial reporting. The content includes forward-looking statements, business overview, strategy, and operational highlights typical of an interim or quarterly report. The document length is substantial (15,000 characters), indicating it is the report itself rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-05-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated Interim Financial Statements (Unaudited)' for the three and six months ended March 31, 2023, and March 31, 2022. It contains detailed financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, and cash flow statements. The document also includes notes on the nature of operations, basis of presentation, and accounting policies. The presence of unaudited condensed interim consolidated financial statements for a period shorter than a full fiscal year, with substantive financial data and analysis, clearly identifies this as an Interim / Quarterly Report. The document is lengthy (15,000 characters) and contains actual financial data, so it is not a mere announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2023
2023-05-18 English
News release - English.pdf
Regulatory Filings
2023-05-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the acceptance of a peer-reviewed publication related to NetraMark's AI technology applied to lung cancer trials. It discusses the scientific findings and the company's approach but does not contain financial statements, regulatory filings, or detailed financial data. It is not an annual or interim report, earnings release, or any form of regulatory filing. The content is primarily informational about a scientific publication and company technology validation, typical of a general regulatory announcement or news release. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-05-10 English
News release - English.pdf
Regulatory Filings
2023-05-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.